Some medical societies say recent studies may have overstated the risks of lung cancer screening, potentially discouraging eligible patients from being screened. While debates continue about false positives and overdiagnosis, many experts agree that routine screening with low-dose CT has clear benefits for people at high risk of lung cancer.

Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.

The landscape for stage IV driver mutation-negative NSCLC is shifting toward even greater precision. ASCO has released critical updates to the Living Guidelines, emphasizing that the “absence” of a driver mutation is a vital biomarker in itself.

An interview with Joshua Reuss, MD, thoracic medical oncologist at Georgetown University and co-author of the guidelines.

Researchers at Texas A&M University have developed a single-injection treatment to aid heart recovery after a heart attack. Following a myocardial infarction, the heart naturally releases atrial natriuretic peptide (ANP), a hormone that reduces cardiac stress and limits long-term damage — but in insufficient quantities. To address this, the team leveraged self-amplifying RNA (saRNA) technology: a one-time intramuscular injection (administered with a standard syringe into the arm) temporarily instructs muscle cells to produce elevated levels of ANP, which then enters the bloodstream and reaches the heart over several weeks. In animal models, the treatment reduced scarring, preserved healthy heart muscle, improved pumping function, and lowered the risk of post-infarction complications. Compared to the team’s earlier approaches — such as surgically implanted cardiac patches — this method is far simpler and more practical, with the potential to meaningfully improve both clinical workflow and patient outcomes.

The new approach uses an injection that prompts the body to release a natural heart protective hormone for weeks.

Tumour heterogeneity refers to the complexity of cell subpopulations coexisting within the tumour microenvironment (TME), such as proliferating tumour cells, tumour stromal cells and infiltrating immune cells.